Phasebio Pharmaceuticals Inc (PHAS) SEC Filing 8-K Material Event for the period ending Monday, July 1, 2019

Phasebio Pharmaceuticals Inc

CIK: 1409661 Ticker: PHAS

View differences made from one to another to evaluate Phasebio Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Phasebio Pharmaceuticals Inc.


Assess how Phasebio Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Phasebio Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Phasebio Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: PHAS
CIK: 1169245
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-024169
Submitted to the SEC: Mon Jul 01 2019 8:02:37 AM EST
Accepted by the SEC: Mon Jul 01 2019
Period: Monday, July 1, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: